Evidence map›Paper›PMID 38273887›Full record

ArticleEClinicalMedicine2024

Dysanapsis is differentially related to lung function trajectories with distinct structural and functional patterns in COPD and variable risk for adverse outcomes.

James C Ross, Raul San José Estépar, Sam Ash, Carrie Pistenmaa, MeiLan Han, Surya P Bhatt, Sandeep Bodduluri, David Sparrow, Jean-Paul Charbonnier, George R Washko and 1 more

Abstract read
In one paragraph

Article in EClinicalMedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Observational
  4. Opportunistic Screening on Chest CT, From theAJR. American journal of roentgenology · 2026
    Review
  5. The Developmental Origins of Asthma and COPD.Annual review of physiology · 2026
    Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

James C RossDepartment of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Raul San José EstéparDepartment of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Sam AshDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Carrie PistenmaaDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
MeiLan HanDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.
Surya P BhattDivision of Pulmonary, Allergy and Critical Care Medicine; University of Alabama at Birmingham, Birmingham, AL, USA.
Sandeep BodduluriDivision of Pulmonary, Allergy and Critical Care Medicine; University of Alabama at Birmingham, Birmingham, AL, USA.
David SparrowVA Normative Aging Study, Veterans Affairs Boston Healthcare System, Boston, MA, USA.
Jean-Paul CharbonnierThirona, Nijmegen, Netherlands.
George R WashkoDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Alejandro A DiazDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Funding

Genetic Epidemiology of COPDU01HL089897 · NHLBI · NATIONAL JEWISH HEALTH · PI CRAPO, JAMES D · 2007 to 2021
$56.9M
Genetic Epidemiology of COPDU01HL089856 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI SILVERMAN, EDWIN K · 2007 to 2021
$20.7M
Risk Stratification for COPD Exacerbations with CT Analysis and Multidimensional Trajectory SubtypingR01HL164380 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI James Ross · 2023 to 2026
$3.2M
Clinical Implications, Genomics, and Transcriptions of Mucus Plugging in SmokersR01HL149861 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI CHO, MICHAEL H., DIAZ, ALEJANDRO · 2020 to 2023
$3.2M
Clinical Implications of Bronchiectasis in SmokersR01HL133137 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI DIAZ, ALEJANDRO · 2017 to 2021
$2.9M
Prognostic Markers of Emphysema ProgressionR01HL149877 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI SAN JOSE ESTEPAR, RAUL · 2020 to 2023
$2.8M
Understanding airway mucus dysfunction in population-based studiesR01HL164824 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI DIAZ, ALEJANDRO · 2022 to 2025
$2.7M
The Pulmonary Vasculature and Platelets in Emphysema and COPDK23HL141651 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI PISTENMAA, CARRIE L · 2019 to 2023
$983k
NHLBI NIH HHS K23 HL141651NHLBI NIH HHS R01 HL133137NHLBI NIH HHS R01 HL149861NHLBI NIH HHS R01 HL149877NHLBI NIH HHS R01 HL164380NHLBI NIH HHS R01 HL164824NHLBI NIH HHS U01 HL089856NHLBI NIH HHS U01 HL089897
6 · The paper itself

Abstract

Background: Abnormal lung function trajectories are associated with increased risk of chronic obstructive pulmonary disease (COPD) and premature mortality; several risk factors for following these trajectories have been identified. Airway under-sizing dysanapsis (small airway lumens relative to lung size), is associated with an increased risk for COPD. The relationship between dysanapsis and lung function trajectories at risk for adverse outcomes of COPD is largely unexplored. We test the hypothesis that dysanapsis differentially affects distinct lung function trajectories associated with adverse outcomes of COPD. Methods: To identify lung function trajectories, we applied Bayesian trajectory analysis to longitudinal FEV1 and FVC Z-scores in the COPDGene Study, an ongoing longitudinal study that collected baseline data from 2007 to 2012. To ensure clinical relevance, we selected trajectories based on risk stratification for all-cause mortality and prospective exacerbations of COPD (ECOPD). Dysanapsis was measured in baseline COPDGene CT scans as the airway lumen-to-lung volume (a/l) ratio. We compared a/l ratios between trajectories and evaluated their association with trajectory assignment, controlling for previously identified risk factors. We also assigned COPDGene participants for whom only baseline data is available to their most likely trajectory and repeated our analysis to further evaluate the relationship between trajectory assignment and a/l ratio measures. Findings: We identified seven trajectories: supranormal, reference, and five trajectories at increased risk for mortality and exacerbations. Three at-risk trajectories are characterized by varying degrees of concomitant FEV1 and FVC impairments and exhibit airway predominant COPD patterns as assessed by quantitative CT imaging. These trajectories have lower a/l ratio values and increased risk for mortality and ECOPD compared to the reference trajectory. Two at-risk trajectories are characterized by disparate levels of FEV1 and FVC impairment and exhibit mixed airway and emphysema COPD patterns on quantitative CT imaging. These trajectories have markedly lower a/l ratio values compared to both the reference trajectory and airway-predominant trajectories and are at greater risk for mortality and ECOPD compared to the airway-predominant trajectories. These findings were observed among the participants with baseline-only data as well. Interpretation: The degree of dysanapsis appears to portend patterns of progression leading to COPD. Assignment of individuals-including those without spirometric obstruction-to distinct trajectories is possible in a clinical setting and may influence management strategies. Strategies that combine CT-assessed dysanapsis together with spirometric measures of lung function and smoke exposure assessment are likely to further improve trajectory assignment accuracy, thereby improving early detection of those most at risk for adverse outcomes. Funding: United States National Institute of Health, COPD Foundation, and Brigham and Women's Hospital.

Indexed as

Anatomic variationChronic obstructive pulmonary diseaseDysanapsisLungLung function trajectories

Identifiers

PMID38273887
PMCPMC10809101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.